Lower Optimal Treatment Adherence Among Youth Living With HIV in a Universal Health Care Setting Where ART Is Available at No Cost.


Journal

The Journal of adolescent health : official publication of the Society for Adolescent Medicine
ISSN: 1879-1972
Titre abrégé: J Adolesc Health
Pays: United States
ID NLM: 9102136

Informations de publication

Date de publication:
04 2019
Historique:
received: 31 05 2018
revised: 01 10 2018
accepted: 02 10 2018
pubmed: 14 12 2018
medline: 25 7 2020
entrez: 15 12 2018
Statut: ppublish

Résumé

We assessed differences in optimal adherence between youth (aged 15-29 years) and adults (aged ≥30 years) enrolled in the British Columbia Centre for Excellence in HIV/AIDS Drug Treatment Program from 2010 to 2016. Population-level clinical data were used to compare optimal antiretroviral therapy adherence (≥95%), based on pharmacy refill data, among youth and adults. Unadjusted and adjusted generalized estimating estimates were performed to examine the independent relationship between time-dependent age categories and optimal adherence, adjusting for confounders. Factors associated with optimal adherence among youth were examined. Data for 7,485 individuals living with HIV were included. Median follow-up was 7 years (Q1-Q3: 4-7). Over the study period, the number of individuals categorized as "youth" ranged from 820 in 2010 to 291 in 2016. Multivariable models found youth living with HIV were significantly less likely to be optimally adherent than adults (adjusted odds ratio [aOR] = .55; 95% confidence interval [CI]: .49-.62), after controlling for potential confounders, although youth adherence improved significantly during the study period. Among youth, increasing time-dependent age (aOR = 1.18/year older; 95%CI: 1.11-1.25) and number of years on antiretroviral therapy (aOR = 1.15, 95%CI: 1.10-1.19) were independently associated with optimal adherence, while Hepatitis C-positive serostatus (aOR = .55; 95%CI: .33-.92) and multiple treatment regimen change (aOR = .89/regimen change; 95%CI: .81-.97) were negatively associated with optimal adherence. Youth were less likely to be optimally adherent throughout the study period. Findings suggest implications for increased youth-centered adherence support, particularly for youth living with HIV concurrently living with Hepatitis C, newly initiating treatment, and going through medication change.

Identifiants

pubmed: 30545583
pii: S1054-139X(18)30445-2
doi: 10.1016/j.jadohealth.2018.10.001
pii:
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-515

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Kalysha Closson (K)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Alexis Palmer (A)

Faculty of Health Sciences, Simon Fraser University, Barnaby, British Columbia, Canada.

Kate Salters (K)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Cathy Puskas (C)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Surita Parashar (S)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Lateefa Tiamiyu (L)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Wendy Zhang (W)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Rolando Barrios (R)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Angela Kaida (A)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Robert S Hogg (RS)

The British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; Faculty of Health Sciences, Simon Fraser University, Barnaby, British Columbia, Canada. Electronic address: bobhogg@cfenet.ubc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH